How does the bowel cancer screening kit work?

The National Bowel Cancer Screening Program sends a faecal immunochemical test (FIT) kit by post to eligible Australians (now ages 45–74). The kit requires collecting a small stool sample at home — no bowel preparation, no fasting, no clinic visit — which is then returned by post. Results come back within a few weeks. A negative result means no blood was detected in the sample and no further action is required until your next invitation (usually every two years). A positive result means blood was detected and warrants further investigation, usually a colonoscopy — it does not mean cancer has been found. Most positive FITs lead to colonoscopy findings of polyps or benign conditions, not cancer.

I'm 45 and haven't received a kit. What should I do?

Invitations are sent by post to the address registered with Medicare. If your Medicare address is out of date, you may not receive the invitation. Contact Medicare (132 011) to update your address, or ask your GP to order a FIT test independently. If you have symptoms — rectal bleeding, persistent change in bowel habit, unexplained iron deficiency, or unexplained weight loss — do not wait for a screening invitation. See your GP, who can arrange investigation outside the screening programme.

Bowel cancer screening: only 42% completing their kit

What just happened

The Australian Institute of Health and Welfare released its June 2026 monitoring report for the National Bowel Cancer Screening Program (NBCSP), and RACGP newsGP covered the figures on 18 June.

The headline number: 42% of the 6.4 million eligible Australians who received an invitation between January 2023 and December 2024 completed their bowel cancer screening kit and returned it. That means 58% — more than half of everyone the programme reaches — did not screen.

The mortality improvement is real and significant. Bowel cancer deaths among those aged 50–74 have fallen by nearly 50% since 2006, the year the NBCSP began. That number represents thousands of lives. And yet, with only 42% participation, a substantial proportion of the benefit that population-level screening could deliver is going unrealised.

The both-and

The programme is working in the people who use it. The opportunity gap is in the majority who don’t.

What the AIHW data shows

Of the 6.4 million people invited, approximately 2.7 million (42%) completed the faecal immunochemical test (FIT) and returned their kit. Among those aged 45–49 — the newer, younger eligibility cohort added when the programme expanded downward in 2024 — 56.2% of those who requested a kit completed the test, and 4.7% returned a positive result that warranted further investigation.

The 83.5% reinvitation return rate is worth noting. People who screen once tend to continue. The challenge is not adherence among participants — it is the initial decision to participate at all.

The AIHW report identifies GP recommendation as the most evidence-supported lever for improving participation. When a GP explicitly recommends bowel cancer screening — not merely mentions it in passing, but advocates for it as a clinical priority — patient completion rates improve substantially. The direct recommendation from a known and trusted clinician carries a legitimacy that the mailed government invitation alone does not.

The 45–49 context

Until recently, the NBCSP recommended screening from age 50. Eligibility now extends to 45–49-year-olds, reflecting evidence that early-onset bowel cancer in younger Australians has been rising over the past two decades. Bowel cancer in under-50s accounts for a small but growing proportion of total cases, and the biology is often more aggressive — partly because it tends to be caught later in people who do not expect to be at risk.

If you are 45 or older and have not received a screening kit, it is worth confirming that the address held on your Medicare record is current. Invitations are sent by post; an out-of-date address means no invitation arrives.

The 4.7% positive FIT rate in the 45–49 cohort is clinically meaningful. A positive FIT does not diagnose bowel cancer — it detects blood in the stool that warrants investigation, usually a colonoscopy. In a population of that age group with a 4.7% positive rate, the yield of clinically significant findings — early cancers, precancerous polyps, other relevant pathology — justifies the investigation. Polyps removed before they become malignant are the mechanism by which screening reduces mortality.

Why participation remains low

The FIT kit is designed to be low-barrier: a home-based sample, returned by post, no preparation required, no time off work, no hospital visit. The reasons for non-completion are rarely logistical. They are mostly psychological.

Some people avoid screening from anxiety about what they might find. Fear of a positive result, and of the colonoscopy that follows, outweighs the abstract reassurance of a negative one. Some find the sample collection process embarrassing. Many simply receive the invitation at a busy moment, set it aside, and find that the urgency fades before the kit is returned.

And some do not understand why it matters — particularly people who feel well, have no symptoms, and have not had a GP frame the programme in terms of the actual mortality data. The statistics are not abstract: the 50% mortality reduction since 2006 is a real outcome that the programme is delivering for people who participate. That framing, from a GP in a room with a patient, is what the data shows changes behaviour.

2 cents

If you are 45 or older and have not yet screened, a single question is worth asking: where is my kit?

If you haven’t received one, check whether your Medicare address is current. If you received a kit and set it aside without returning it — you are not unusual, and the programme will send another. Returning the kit takes approximately five minutes.

A negative result gives two years of reassurance. A positive result is not a diagnosis of cancer; it is a prompt to look more closely, while any lesion is still small enough to be treated effectively. Bowel cancer caught at stage 1 has a 5-year survival rate above 90%. Bowel cancer caught at stage 4 does not.

If you have symptoms — blood in the stool, a persistent change in bowel habit, unexplained iron deficiency anaemia, unexplained weight loss — do not wait for a screening invitation. See your GP, who can arrange investigation independently of the NBCSP programme.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

Bowel cancer is Australia’s second most common cause of cancer death, and a programme demonstrably reducing mortality by nearly 50% is reaching only 42% of those it invites. The gap between what the programme could achieve and what it is achieving is filled by inertia and the absence of a direct clinical conversation. If your GP has not raised bowel cancer screening with you and you are 45 or older, it is worth raising with them.